The neuroendocrine tumors therapeutics market will register a CAGR of close to 9% by 2023

Wednesday, May 1, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, April 30, 2019 /PRNewswire/ --About this marketThe increasing research grants and funding are contributing to the neuroendocrine tumors therapeutics market growth in the forthcoming years. Various government and non-government organizations are focusing on providing grants and funding to create an awareness about neuroendocrine tumors. These programs also

help in better and quicker development of therapies for the treatment of neuroendocrine tumors. Furthermore, the grants are expected to accelerate the research and strengthen the drug development pipeline of neuroendocrine tumors, thus, impacting the market growth positively over the next few years. Analysts have predicted that the neuroendocrine tumors therapeutics market will register a CAGR of close to 9% by 2023.Download the full report: https://www.reportbuyer.com/product/5772564/?utm_source=PRN Market OverviewThe advent of radiolabeled drugsOne of the growth drivers of the global neuroendocrine tumor's therapeutics market is the advent of radiolabeled drugs. Due to their high efficacy with less adverse effects, such novel drugs receive high adoption from medical practitioners, which broadens the overall patient base and drives the market growth.Increasing preference for alternative treatmentsOne of the challenges in the growth of the global neuroendocrine tumor's therapeutics market is the increasing preference for alternative treatments. Therapeutic approaches remain costly, more time consuming, and non-remissive in nature, which makes them less preferred treatment options among patients as well as medical practitioners, which poses a challenge to market growth.For the detailed list of factors that will drive and challenge the growth of the neuroendocrine tumors therapeutics market during 2019-2023, view our report.Competitive LandscapeThe market appears to be highly concentrated with the presence of a few market players. Vendors are focusing on extensive research for identifying the attributes of neuroendocrine tumors through a genomic approach, as the identification of mutated genes is one of the biggest challenges for developing target therapies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.Download the full report: https://www.reportbuyer.com/product/5772564/?utm_source=PRN About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: sarah@reportbuyer.com Tel: +1 (718) 213 4904 Website: www.reportbuyer.com

Cision View original content:http://www.prnewswire.com/news-releases/the-neuroendocrine-tumors-therapeutics-market-will-register-a-cagr-of-close-to-9-by-2023-300841130.html

SOURCE ReportBuyer



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store